Pol Theta Enzyme Identified as Key Driver of Cancer Resilience

Why It Matters

Because many cancers depend on Pol θ‑driven MMEJ to survive replication stress, blocking this pathway could enhance the efficacy of existing DNA‑damage therapies and provide a selective therapeutic window.

Key Takeaways

• Pol θ drives MMEJ at broken replication forks
• Fork‑MMEJ differs mechanistically from canonical MMEJ
• ATR suppresses fork‑MMEJ, steering repair toward BIR
• Pol θ inhibitors synergize with ATR blockers in cancer cells
• Targeting fork‑MMEJ may spare normal cells

Pulse Analysis

Replication stress is a hallmark of aggressive tumors, forcing cells to constantly repair stalled or broken forks. While break‑induced replication (BIR) was long considered the primary rescue mechanism, the new Molecular Cell study reveals that microhomology‑mediated end joining (MMEJ) operates at the fork itself, driven by Pol θ. This early‑stage, error‑prone pathway creates the uneven deletions that populate cancer genomes, explaining how malignant cells tolerate otherwise lethal DNA damage.

The researchers combined CRISPR nickase‑induced fork collapse, live‑cell reporters, and deep sequencing to map repair outcomes with unprecedented precision. They identified RPA as the initiator of fork‑MMEJ and showed that ATR acts as a molecular switch, suppressing Pol θ activity and diverting repair toward the slower, high‑fidelity BIR route. When both ATR and Pol θ are inhibited, cancer cells experience catastrophic genomic instability, whereas normal cells—less burdened by replication stress—remain largely unaffected.

Clinically, these insights reshape the strategy for targeting DNA‑repair vulnerabilities. Pol θ inhibitors, already in early trials for BRCA‑mutated tumors, may achieve broader efficacy when paired with ATR inhibitors, a class also advancing through oncology pipelines. The dual‑target approach promises a higher therapeutic index, potentially expanding the market for precision‑medicine combos that exploit synthetic lethality in replication‑stressed cancers. Future work to map additional fork‑MMEJ components could generate new drug targets, reinforcing the commercial and scientific relevance of this pathway.